Back to search
Relapsed/Refractory Pediatric B-ALL
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Relapsed/Refractory Pediatric B-ALL trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Relapsed/Refractory Pediatric B-ALL trials you may qualify forThe main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion tha…
This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will eval…
The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-r…
A Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in chil…
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of diff…
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants wit…
This is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial conducted in patients with relapsed or refractory pediatric B-cell a…